In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

The author highlights the real-life impacts on the residents of Knoxville and East Tennessee from Trump administration cuts ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

Royalty, a buyer of biopharmaceutical royalties, already receives a cut of the sales of Biogen’s Tysabri and Spinraza. The firm secured those royalties through deals with Ionis and Perrigo ...

The firm expanded its neurology portfolio beyond MS, including the blockbuster Spinraza for spinal muscular atrophy, or SMA, a rare neuromuscular disease. We see Biogen as a firm in transition ...

the new agreement is fitting since Biogen already has a foothold in the field of uncommon nervous system disorders. Not only does the company have Spinraza, it also sells the Friedreich’s ataxia ...

Spinraza. Excluding certain items, Biogen earned $3.44 per share in the fourth quarter ended December 31, compared with estimates of $3.35. Total revenue rose about 3% to $2.46 billion.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...